Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPARE-VOE: Individualized vs Weight-Based Opioids for Sickle Cell Pain
NCT03933397Phase 3Terminated
- Sponsor
- Duke University
- Start
- Aug 2019
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of morphine, hydromorphone in sickle cell disease (SCD), sponsored by Duke University. Started Aug 2019; status: terminated.
02
Drugs
morphinehydromorphone
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03933397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933397.